This study aimed to evaluate the effects of Insulin Degludec/Insulin Aspart (IDegAsp) as an intensification treatment for glycemic control in patients with type 2 diabetes (T2D) in a real-world clinical setting. This evidence concerns the gene INS and type 2 diabetes mellitus.